Lower numbers = closer to natural. Higher numbers = more enhanced.
Why this rating?
A statin: an HMG-CoA reductase inhibitor prescribed to lower LDL cholesterol. It has no anabolic, androgenic or ergogenic action and does not raise the natural ceiling by any path. It appears in this archive because AAS use, particularly oral 17-alpha-alkylated compounds, routinely wrecks the lipid panel, and this is the drug that addresses it. Rated 1 (basically natty).
Overview
One of the most potent statins available and the standard pharmaceutical answer to the lipid damage that steroid cycles cause. Oral 17-alpha-alkylated compounds in particular can crater HDL and drive LDL up sharply within weeks, an effect no amount of fish oil meaningfully offsets. This is the intervention that actually moves those numbers, and it is prescription medicine rather than a supplement.
Important Warnings
- •Prescription medication: dose to a measured lipid panel under medical supervision, not by guesswork
- •Patients of Asian descent should start at 5mg daily due to ~2-fold higher plasma exposure
- •Maximum 10mg daily if creatinine clearance is below 30 mL/min
- •Proteinuria is most frequent at 40mg or above
- •Contraindicated in acute liver failure, decompensated cirrhosis, unexplained persistent transaminase elevations, and pregnancy
- •Myopathy risk increases with fibrates, colchicine, niacin and red yeast rice
- •Cyclosporine, protease inhibitors, ritonavir, cobicistat and dronedarone raise rosuvastatin levels
- •Does NOT restore the HDL suppressed by oral steroids. It is an LDL drug
- •Seek medical attention for severe unexplained muscle pain, weakness or dark urine
Purpose & Use Cases
Correcting Cycle-Induced Dyslipidemia
The reason it belongs in this archive. Androgens: especially oral 17-alpha-alkylated steroids, suppress HDL and raise LDL, often dramatically and quickly. A statin directly addresses the LDL side of that damage.
Long-Term Cardiovascular Risk Management
For anyone on long-term TRT or repeated blast-cruise cycles, cumulative atherosclerotic risk is the realistic long-horizon threat, not the acute sides people worry about. Statins have demonstrated efficacy in both primary and secondary prevention of cardiovascular events including myocardial infarction and stroke.
Benefits
- High-intensity dosing (20-40mg daily) achieves LDL-C reduction of 50% or greater
- Moderate-intensity dosing (5-10mg daily) achieves 30-49% LDL-C reduction
- Demonstrated efficacy in both primary and secondary prevention of cardiovascular events
- Long ~19-hour half-life allows simple once-daily dosing at any time of day
- Addresses the single most under-managed consequence of long-term AAS use
- Cheap as a generic and easily monitored with a standard lipid panel
Good to Know
The lipid damage is the under-rated cost of a cycle
Most attention goes to acne, hair and gyno. The change that actually predicts long-term outcomes is the lipid panel. Androgens, and oral 17-alpha-alkylated compounds especially, can suppress HDL and raise LDL sharply within weeks. That damage is silent, cumulative and invisible without bloodwork.
It fixes LDL, not HDL
A statin lowers LDL very effectively. It does not restore the HDL that oral steroids suppress. Nothing reliably does. The actual fix for crushed HDL is coming off the compound causing it. Do not read a normalised LDL as "lipids handled".
Dose to a number, not to a feeling
Statin dosing is titrated against an actual measured lipid panel at 4-week-or-longer intervals. This is the clearest example in the archive of a compound where bloodwork is not optional, without it you are dosing blind.
Two hard dose caps most people miss
Patients of Asian descent should start at 5mg daily because plasma exposure is roughly 2-fold higher, and anyone with CrCl below 30 mL/min is capped at 10mg. Proteinuria also becomes most frequent at 40mg or above.
Dosage Guidelines
| Experience Level | Dosage Range |
|---|---|
| Beginner | 5 – 10 mg/day |
| Intermediate | 10 – 20 mg/day |
| Advanced | 20 – 40 mg/day |
Dosing is defined by intensity rather than by user experience: 5-10mg/day is moderate-intensity (30-49% LDL reduction) and 20-40mg/day is high-intensity (≥50% LDL reduction). Titrate at intervals of 4 weeks or more, guided by an actual lipid panel rather than guesswork. Two important dose caps: patients of Asian descent should be initiated at 5mg once daily because plasma exposure is approximately 2-fold higher, and in renal impairment with CrCl <30 mL/min the starting dose is 5mg with a 10mg maximum. Proteinuria was most frequent at doses of 40mg or greater. This is not a compound to self-prescribe blindly. It is dosed to a measured lipid target under medical supervision.
Peak plasma concentration is reached 3-5 hours post-dose, with bioavailability of roughly 20% and 88% protein binding (primarily albumin). Around 90% is excreted via the biliary/fecal route and only ~10% renally. The long half-life is why once-daily dosing works and why timing relative to a workout or meal is irrelevant.
Side Effects
Myalgia / muscle aches
commonMuscle cramps, aches and weakness are the classic statin complaint and occur with all statins in this class. Relevant here because lifters may misattribute training soreness, or vice versa.
Dose reduction or switching statin often resolves it. CoQ10 is commonly used for this, though the trial evidence is genuinely mixed. Report persistent or severe symptoms.
Myopathy / rhabdomyolysis
rareSevere myopathy and rhabdomyolysis are the serious muscle-related risks, marked by creatine kinase greater than 10 times the upper limit of normal, and can progress to statin-induced acute kidney injury.
Seek medical attention for severe unexplained muscle pain, weakness or dark urine. Risk rises with fibrates, colchicine, niacin, red yeast rice and drugs that raise rosuvastatin levels.
Hepatotoxicity
uncommonTransaminase elevations greater than 3 times the upper limit of normal can occur. This matters disproportionately here because oral 17-alpha-alkylated steroids independently strain the liver.
Baseline liver function tests before initiating, then periodically. Discontinue if hepatic injury with hyperbilirubinemia occurs.
New-onset diabetes mellitus
uncommonStatins are associated with new-onset diabetes. Worth weighing alongside other compounds affecting glucose handling.
Monitor fasting glucose and HbA1c, particularly when running GH or insulin.
Proteinuria / hematuria
uncommonProteinuria was most frequent in patients taking 40mg or more of rosuvastatin.
Baseline serum creatinine and creatinine clearance. Avoid the 40mg dose unless specifically indicated.
Headache, nausea, arthralgia
commonMild and generally self-limiting.
Usually resolves with continued use.
General Mitigation Strategies
Statins are among the best-characterised drugs in medicine and are well tolerated by most people. The specific overlaps that matter for this population are: liver strain that compounds with oral 17-alpha-alkylated steroids, muscle symptoms that can be confused with training damage, and the new-onset diabetes association if you are also running GH or insulin. Monitoring is straightforward, lipid panel at baseline, 4-12 weeks after starting or adjusting, then every 3-12 months; liver function at baseline and if symptoms suggest hepatotoxicity; creatine kinase only where there is a history of statin intolerance, a drug interaction, or unexplained muscle symptoms.
Support Supplements
Ancillary supplements commonly run alongside Rosuvastatin to manage side effects, support the target tissue, or fill nutrient demands it creates.
Lipid panel + liver function bloodwork
KeyStatin dosing is titrated to a measured target; both statins and oral steroids affect the liver
- Timing
- Baseline, 4-12 weeks after starting or adjusting, then every 3-12 months
CoQ10
Commonly used for statin-associated muscle symptoms
- Dose
- 100-200mg daily
- When
- Meta-analysis evidence is genuinely conflicting, some find benefit for muscle pain, others find none
Post Cycle Therapy (PCT)
No HPT axis interaction. No PCT implications.
How It Works
Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. Reduced intracellular cholesterol causes the liver to upregulate LDL receptors, which pulls circulating LDL cholesterol out of the blood. The result is a dose-dependent reduction in LDL-C and total cholesterol, and a corresponding reduction in atherosclerotic cardiovascular risk.
Hormonal & Androgenic Profile
N/A: not an androgen.
Not a hormonal drug: no aromatase or estrogen relevance.
Strongly protective, which is the entire point. It directly counteracts the LDL elevation caused by androgens. Note it does NOT fix the HDL suppression that oral steroids cause. Statins are an LDL drug, and no pharmaceutical reliably restores AAS-crushed HDL.
Fundamentals
Reference on the practices relevant to Rosuvastatin: how they are done and where they go wrong. Not a recommendation to use it.
Common Stacks
- Rosuvastatin + Ezetimibe: complementary mechanisms, a further 24% LDL reduction in IMPROVE-IT
- Rosuvastatin alongside any oral 17-AA cycle, with liver monitoring
- Rosuvastatin + TUDCA + omega-3 as a broader cardiovascular/hepatic support protocol
Legal Status
FDA-approved for hyperlipidemia, mixed dyslipidemia, homozygous familial hypercholesterolemia, primary dysbetalipoproteinemia, hypertriglyceridemia, and primary ASCVD prevention in high-risk patients without confirmed coronary heart disease. Not a controlled substance.
Legal status varies by country and changes over time. This is a general summary, not legal advice.
WADA Status
A lipid-lowering medication with no performance-enhancing action. Not listed on the WADA Prohibited List.